share_log

Red Light Holland Initiates Psilocybin Extraction Phase With PharmAla Following Successful Testing and Preparation by CCrest Labs

Red Light Holland Initiates Psilocybin Extraction Phase With PharmAla Following Successful Testing and Preparation by CCrest Labs

继CCrest Labs成功进行测试和准备之后,Red Light Holland与PharMala启动了迷幻药提取阶段
newsfile ·  04/23 06:11

Toronto, Ontario--(Newsfile Corp. - April 23, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland"), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws, is pleased to announce the successful completion of the initial testing and dehydration of psilocybin truffles at CCrest Laboratories Inc. ("CCrest Labs") in Montreal, Canada. Following this advancement, the dehydrated truffles have been shipped to a lab collaborating with PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) ("PharmAla") for the next phase of extraction and research.

安大略省多伦多--(Newsfile Corp.,2024年4月23日)——Red Light Holland Corp.(CSE:TRIP)(FSE:4YX)(OTCQB:TRUFF)(“Red Light Holland”),一家在北美和欧洲生产、种植和销售功能性蘑菇和蘑菇家用种植套件以及向荷兰合法娱乐市场销售优质迷幻药松露品牌的公司所有适用的法律,很高兴地宣布,CCrest Laboratories Inc.(“CCrest Labs”)成功完成了对迷幻药松露的初步测试和脱水工作加拿大蒙特利尔。继这一进展之后,脱水松露已运往与PharMala Biotech Holdings Inc.(CSE:MDMA)(OTCQB:MDXF)(“PharMala”)合作的实验室,用于下一阶段的提取和研究。

Earlier this month, on April 8th, 2024, Red Light Holland initiated its most substantial shipment yet - 5 kg (5000 grams) of freshly cultivated psilocybin truffles from its farm in the Netherlands to CCrest Labs. This operation conducted by CCrest Labs, after a Health Canada approved psilocybin import permit, is a testament to the rigorous standards and collaborative framework guiding this international venture.

本月早些时候,即2024年4月8日,Red Light Holland开始了迄今为止最大批量的——从其荷兰农场向CCrest实验室运送5千克(5000克)新鲜培育的迷幻药松露。在获得加拿大卫生部批准的迷幻药进口许可证后,由CCrest Labs开展的这项行动证明了指导该国际企业的严格标准和合作框架。

CCrest Labs, a cGMP-certified pharmaceutical laboratory, has meticulously completed the dehydration process of the truffles and baseline testing of psychoactive materials (psilocybin & psilocin). The dehydrated truffles have been shipped to PharmAla's development laboratory, Chiral Labs, for extraction. This extraction process is aimed at refining and stabilizing the psilocybin, which is essential for longer shelf life and developing a product intended for clinical research and emerging markets.

CCrest Labs是一家获得CGMP认证的药物实验室,精心完成了松露的脱水过程和精神活性物质(迷幻药和迷幻药)的基线测试。脱水松露已运往PharMala的开发实验室Chiral Labs进行提取。该提取过程旨在提炼和稳定迷幻药,这对于延长保质期和开发用于临床研究和新兴市场的产品至关重要。

"With the successful testing and preparation of our psilocybin truffles at CCrest Labs, we are now moving into an exciting phase of extraction with PharmAla. This step is critical in our ongoing efforts to unlock the therapeutic potential of psilocybin and develop a commercial-scale process for manufacturing natural-source Active Pharmaceutical Ingredients (API)," said Todd Shapiro, CEO and Director of Red Light Holland.

“随着我们在CCrest实验室成功测试和制备我们的迷幻药松露,我们现在正进入一个令人兴奋的PharMala提取阶段。红光荷兰首席执行官兼董事托德·夏皮罗说,这一步骤对于我们持续努力释放迷幻药的治疗潜力以及开发生产天然来源活性药物成分(API)的商业规模工艺至关重要。

Red Light Holland remains dedicated to advancing psychedelic research and is committed to keeping stakeholders informed on the progress and results of this collaboration.

Red Light Holland仍然致力于推进迷幻研究,并致力于让利益相关者随时了解此次合作的进展和结果。

About Red Light Holland

荷兰红光简介

Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws.

Red Light Holland是一家总部位于安大略省的公司,根据所有适用法律,在北美和欧洲从事功能性蘑菇和蘑菇家庭种植套件的生产、种植和销售,以及向荷兰合法娱乐市场销售psilocybin松露的优质品牌。

For additional information on the Company:

有关公司的更多信息:

Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-TRIP (8747)
Email: todd@redlight.co
Website:

托德·夏皮罗
首席执行官兼董事
电话:647-643-TRIP (8747)
电子邮件:todd@redlight.co
网站:

About PharmAla

关于 Pharmala

PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla's research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a "regulatory first" organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators.

PharMala Biotech Holdings Inc.(CSE:MDMA)(场外交易代码:MDXXF)是一家生物技术公司,专注于研究、开发和制造包括摇头丸在内的MDX类分子。PharMala的创立有两个重点:缓解全球积压的仿制药临床级摇头丸,以便在特定司法管辖区进行临床试验和商业销售,以及开发同类新药。PharMala是目前唯一一家为临床试验以外的患者治疗提供临床级摇头丸的公司。PharMala 的研发部门已经完成了对多个知识产权家族的概念验证研究,包括其主要候选药物 ALA-002。PharMala是一个 “监管第一” 组织,成立的原则是,迷幻药行业的真正成功只能通过与监管机构的良好关系才能实现。

For more information, please contact:

欲了解更多信息,请联系:

Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website:

尼古拉斯·卡迪什
首席执行官
PharmaLa 生物科技控股有限公司
电子邮件:press@PharmAla.ca
电话:1-855-444-6362
网站:

About Shaman Pharma Corp.

关于萨满制药公司

Shaman Pharma is a federally registered Canadian corporation with the mission to power outstanding psychedelic life science innovation. Accelerating time-to-market through its portfolio of assets, Shaman launches and consolidates revenue-driven pharma-biotech life sciences ventures focused on supplying psychedelic drugs & novel active ingredients.

Shaman Pharma是一家在联邦政府注册的加拿大公司,其使命是推动卓越的迷幻生命科学创新。萨满通过其资产组合加快了上市时间,启动并整合了以收入为导向的制药生物技术生命科学企业,专注于提供迷幻药物和新型活性成分。

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

关于前瞻性陈述的警示性说明

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events.

本新闻稿包含适用的加拿大证券立法所指的 “前瞻性信息”。这些陈述与未来的事件或未来的表现有关。使用任何 “可能”、“打算”、“期望”、“相信”、“将”、“预计”、“估计” 以及与非历史事实的事项相关的类似表达方式和陈述均旨在识别前瞻性信息,并基于公司当前对此类未来事件的结果和时机的看法或假设。

The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company's performance, business objectives and milestones and the anticipated timing thereof, and costs in connection with, the execution or achievement of such objectives and milestones, including its plans to continue seeking legal opportunities to increase responsible access to natural psilocybin around the world and PharmAla's development and distribution of the Company's psilocybin; the Company and the Company's partners to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the expectations with respect to the Company's latest Health Canada approved psilocybin import; the Company's continued commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's commitment to making further announcements with respect to its overall R&D project, including its partnership with PharmAla and the research project to develop a process for the commercial manufacture of natural-source Active Pharmaceutical Ingredient (API) derived from the Company's psilocybin truffles; the Company proving out potential therapeutic benefits of Psilocybin; the Company receiving important insights from naturally occurring psilocybin truffles; and The Company's ability to extract and expand access to psilocybin products.

此处包含的前瞻性信息和前瞻性陈述包括但不限于以下方面的陈述:公司的业绩、业务目标和里程碑及其预期时间,以及与执行或实现这些目标和里程碑相关的成本,包括其继续寻求法律机会以增加全球范围内自然迷幻药获取渠道的计划以及PharMala对公司迷幻药的开发和分销;公司和公司的合作伙伴维持其规定的许可证并获得公司执行上述计划所需的所有必要额外许可证和监管部门的批准;对公司最近批准的迷幻药进口的预期;公司继续承诺确保合法、负责任地获得Red Light的标准化天然迷幻药产品;公司承诺进一步宣布其整体研发项目,包括与PharMala的合作以及开发的研究项目一个源自公司迷幻药松露的天然活性药物成分(API)的商业生产流程;公司证明了迷幻药的潜在治疗益处;公司从天然存在的迷幻药松露中获得重要见解;以及公司提取和扩大迷幻药产品准入的能力。

Forward-Looking information in this press release are based on certain assumptions and expected future events, namely: the Company's ability to maintain or exceed its current performance, and carry out its business objectives and milestones and under the anticipated timing and costs in connection with, the execution or achievement of such objectives and milestones; the Company and the Company's partners' abilities, including PharmAla and CCrest Laboratories, to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the Company's ability to realize its plans for its latest Health Canada approved psilocybin import; the Company's ability for its continued commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's ability to maintain its commitment to making further announcements with respect to its overall R&D project, including its partnership with PharmAla and their research project to develop a process for the commercial manufacture of natural-source Active Pharmaceutical Ingredient (API) derived from the Company's psilocybin truffles; the Company proving out potential therapeutic benefits of Psilocybin; the Company receiving important insights from naturally occurring psilocybin truffles; and the ability to extract and expand access to psilocybin products.

本新闻稿中的前瞻性信息基于某些假设和预期的未来事件,即:公司维持或超过其当前业绩、实现其业务目标和里程碑的能力,以及在与执行或实现这些目标和里程碑相关的预期时间和成本下的能力;公司和公司的合作伙伴,包括PharMala和CCREST Laboratories,维持其规定许可证并获得所有必要的额外许可和监管部门批准的能力要求公司按上述方式执行其计划;公司实现其最近批准的迷幻药进口计划的能力;公司继续承诺确保合法、负责任地获得Red Light的标准化天然迷幻药产品的能力;公司有能力兑现其就其总体研发项目发布进一步公告的承诺,包括与PharMala的合作以及开发商业工艺的研究项目天然产品的制造-采购源自公司迷幻药松露的活性药物成分(API);公司证明了迷幻药的潜在治疗益处;公司从天然存在的迷幻药松露中获得了重要见解;以及提取和扩大迷幻药产品准入的能力。

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company's inability to maintain or exceed its current performance, and carry out its business objectives and milestones and under the anticipated timing and costs in connection with, the execution or achievement of such objectives and milestones; the Company and the Company's partners' inabilities, including PharmAla and CCrest Laboratories, to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the Company's inability to realize upon its plans for its latest Health Canada approved psilocybin import; the Company's inability to maintain its commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's inability to maintain its commitment to making further announcements with respect to its overall R&D project, including its partnership with PharmAla; and The Company's ability to expand and extract access to psilocybin products.

这些陈述涉及已知和未知的风险、不确定性和其他因素,可能导致实际业绩、业绩或成就与此类声明所表达或暗示的结果存在重大差异,包括但不限于:公司无法维持或超过其当前业绩,无法实现其业务目标和里程碑,在预期的时间和成本下无法执行或实现这些目标和里程碑;公司和公司合作伙伴的无能,包括 PharPhar的资格马拉和CCrest Laboratories将维持其规定的许可证,并获得公司执行上述计划所需的所有必要额外许可证和监管部门的批准;公司无法实现其最近批准的加拿大卫生部批准的迷幻药进口计划;公司无法兑现其承诺,确保合法、负责任地获得红光的标准化天然迷幻药产品;公司无法兑现其就其总体情况发布进一步公告的承诺研发项目,包括与PharMala的合作伙伴关系;以及该公司扩大和提取迷幻药产品准入的能力。

The Company cannot make medical claims and is purely in a R&D phase with its partners CCrest Labs and PharmAla Biotech Holdings inc.

该公司无法提出医疗索赔,其合作伙伴CCrest Labs和PharMala Biotech Holdings inc纯粹处于研发阶段。

Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

进一步提醒读者不要过分依赖前瞻性陈述,因为无法保证前瞻性陈述所依据的计划、意图或预期会实现。尽管管理层在编写时认为此类信息是合理的,但可能被证明是不正确的,实际结果可能与预期的结果存在重大差异。

Forward-Looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

本新闻稿中包含的前瞻性陈述受本警示声明的明确限制,反映了公司截至本文发布之日的预期,此后可能会发生变化。除非适用法律要求,否则公司没有义务更新或修改任何前瞻性陈述,无论是由于新信息、估计或观点、未来事件或结果还是其他原因,也没有义务解释后续实际事件与此类前瞻性信息之间的任何重大差异。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发